Anti-obesity pharmacotherapy in adults with chronic kidney disease
Kidney International, ISSN: 0085-2538, Vol: 105, Issue: 2, Page: 269-280
2024
- 4Citations
- 22Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent Blog
From Weight Loss to Obesity to Cardiorenal Metabolic Health
A profound shift in the understanding of medicines that help with excessive or abnormal fat is underway. A few years ago, everybody thought of these in only one frame of reference – weight loss drugs. But that is changing now. Discourse about them is moving from weight loss to obesity treatment and even further, to cardio, renal, and metabolic health. This change is moving on several fronts. But t
Review Description
Obesity is a leading risk factor for the development and progression of kidney disease and a major barrier to optimal management of patients with chronic kidney disease. While in the past anti-obesity drugs offered only modest weight loss efficacy in exchange for various safety and tolerability risks, a wave of safer, more tolerable, and more effective treatment options is transforming the management of obesity. This review evaluates current and future pharmacologic anti-obesity therapy in adults through a kidney-oriented lens. It also explores the goals of anti-obesity treatment, describes the underlying putative mechanisms of action, and raises important scientific questions that deserve further exploration in people with chronic kidney disease.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0085253823007627; http://dx.doi.org/10.1016/j.kint.2023.10.014; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85180609939&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37926421; https://linkinghub.elsevier.com/retrieve/pii/S0085253823007627; https://dx.doi.org/10.1016/j.kint.2023.10.014
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know